{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T23:20:18Z","timestamp":1770765618340,"version":"3.50.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000960","name":"American College of Rheumatology Research and Education Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000960","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Alliance of Associations for Rheumatology"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11926-025-01202-y","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T08:26:39Z","timestamp":1764145599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A\/B Report: Defining and Structuring the Clinical and Laboratory Domains"],"prefix":"10.1007","volume":"27","author":[{"given":"Medha","family":"Barbhaiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Zuily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Carmen","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadej","family":"Avcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Bertolaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Ware","family":"Branch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Ramires","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien M. J.","family":"Devreese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Frances","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Ortel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya V.","family":"Seshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Willis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Hendry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Naden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen H.","family":"Costenbader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doruk","family":"Erkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on Behalf of New APS Classification Criteria Collaborators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Agmon-Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassyanne","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oral","family":"Alpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ales","family":"Ambrozic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danieli","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Appenzeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahar","family":"Artim Esen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yackov","family":"Berkun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillame","family":"Canaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Chighizola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Costedoat-Chalumeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip G.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"de Moerloose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"De Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Derksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyhan","family":"Diz-Kucukkaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bill","family":"Giannakopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Gomez-Puerto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio B","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Inanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munther","family":"Khamashta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Kriegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Krilis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyal","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Laskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Manneville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patti","family":"Massicotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gale","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal","family":"Mikdashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Myones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Pengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Roubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Sammaritano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arzu","family":"Soybilgic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Tincani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Woller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Yelnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pojen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1202_CR1","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","volume":"42","author":"WA Wilson","year":"1999","unstructured":"Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309\u201311.","journal-title":"Arthritis Rheum"},{"key":"1202_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N","volume":"43","author":"MD Lockshin","year":"2000","unstructured":"Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum. 2000;43:440\u20133.","journal-title":"Arthritis Rheum"},{"key":"1202_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295\u2013306.","journal-title":"J Thromb Haemost"},{"key":"1202_CR4","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1002\/acr.24520","volume":"73","author":"M Barbhaiya","year":"2021","unstructured":"Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of a new international antiphospholipid syndrome classification criteria phase I\/II report: generation and reduction of candidate criteria. Arthritis Care Res Hoboken. 2021;73:1490\u2013501.","journal-title":"Arthritis Care Res Hoboken"},{"key":"1202_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/art.42624","volume":"75","author":"M Barbhaiya","year":"2023","unstructured":"Barbhaiya M, Zuily S, Naden R, et al. The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023;75:1687\u2013702.","journal-title":"Arthritis Rheumatol"},{"key":"1202_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/ard-2023-224609","volume":"82","author":"M Barbhaiya","year":"2023","unstructured":"Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023;82:1258\u201370.","journal-title":"Ann Rheum Dis"},{"key":"1202_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","volume":"79","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, et al. The 2019 American college of rheumatology\/European league against rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79:77\u201387.","journal-title":"Ann Rheum Dis"},{"key":"1202_CR8","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al. 2019 European league against rheumatism\/american college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:1400\u201312.","journal-title":"Arthritis Rheumatol"},{"key":"1202_CR9","doi-asserted-by":"publisher","unstructured":"Barbhaiya M, Zuily S, Jannat-Khah D, Amigo MC, Andrade D, Avcin T, et al. Development of the 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions. Arthritis Care Res (Hoboken). 2025. https:\/\/doi.org\/10.1002\/acr.25599.","DOI":"10.1002\/acr.25599"},{"key":"1202_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25415","author":"M Barbhaiya","year":"2024","unstructured":"Barbhaiya M, Zuily S, Amigo MC, et al. Development of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria, phase III-D report: multi criteria decision analysis. Arthritis Care Res (Hoboken). 2024. https:\/\/doi.org\/10.1002\/acr.25415.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1202_CR11","first-page":"2379","volume":"33","author":"IW Uthman","year":"2006","unstructured":"Uthman IW, Khamashta MA. Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rhuematol. 2006;33:2379\u201382.","journal-title":"J Rhuematol"},{"key":"1202_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0002-9343(99)80014-X","volume":"98","author":"A Escalante","year":"1995","unstructured":"Escalante A, Brey RL, Mitchell BD Jr., Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med. 1995;98:559\u201365.","journal-title":"Am J Med"},{"key":"1202_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1191\/096120398678919688","volume":"7","author":"DG Wahl","year":"1998","unstructured":"Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998;7:15\u201322.","journal-title":"Lupus"},{"key":"1202_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/acr.24468","volume":"74","author":"E Sevim","year":"2022","unstructured":"Sevim E, Zisa D, Andrade D, et al. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository. Arthritis Care Res (Hoboken). 2022;74:324\u201335.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1202_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k351","volume":"360","author":"MJ Stubbs","year":"2018","unstructured":"Stubbs MJ, Mouyis M, Thomas M. Deep vein thrombosis. BMJ. 2018;360: k351.","journal-title":"BMJ"},{"key":"1202_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","volume":"14","author":"MM Abreu","year":"2015","unstructured":"Abreu MM, Danowski A, Wahl DG, et al. The relevance of non-criteria clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force report on antiphospholipid syndrome clinical features. Autoimmun Rev. 2015;14:401\u201314.","journal-title":"Autoimmun Rev"},{"key":"1202_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","volume":"24","author":"HP Adams Jr.","year":"1993","unstructured":"Adams HP Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 1993;24:35\u201341.","journal-title":"Stroke"},{"key":"1202_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000352050","volume":"36","author":"P Amarenco","year":"2013","unstructured":"Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (updated ASCO phenotyping). Cerebrovasc Dis. 2013;36:1\u20135.","journal-title":"Cerebrovasc Dis"},{"key":"1202_CR19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1136\/ard.2008.093179","volume":"68","author":"R Cervera","year":"2009","unstructured":"Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68:1428\u201332.","journal-title":"Ann Rheum Dis"},{"key":"1202_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.thromres.2013.04.012","volume":"132","author":"S Zuily","year":"2013","unstructured":"Zuily S, Regnault V, Guillemin F, et al. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res. 2013;132:e1\u20137.","journal-title":"Thromb Res"},{"key":"1202_CR21","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, et al. American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693\u2013738.","journal-title":"Blood Adv"},{"key":"1202_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315\u201352.","journal-title":"Chest"},{"key":"1202_CR23","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European Association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J. 2016;37:2315\u201381.","journal-title":"Eur Heart J"},{"key":"1202_CR24","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1002\/art.21041","volume":"52","author":"C Franc\u00e8s","year":"2005","unstructured":"Franc\u00e8s C, Niang S, Laffitte E, Pelletier F, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum. 2005;52:1785\u201393.","journal-title":"Arthritis Rheum"},{"key":"1202_CR25","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-4632.2004.01939.x","volume":"43","author":"MJ Di\u00f3genes","year":"2004","unstructured":"Di\u00f3genes MJ, Di\u00f3genes PC, de Morais Carneiro RM, Neto CC, Duarte FB, Holanda RR. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol. 2004;43:632\u20137.","journal-title":"Int J Dermatol"},{"key":"1202_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.4103\/2229-5178.164493","volume":"6","author":"VV Sajjan","year":"2015","unstructured":"Sajjan VV, Lunge S, Swamy MB, Pandit AM. Livedo reticularis: a review of the literature. Indian Dermatol Online J. 2015;6:315\u201321.","journal-title":"Indian Dermatol Online J"},{"key":"1202_CR27","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/rheumatology\/kep036","volume":"48","author":"T Kawakami","year":"2009","unstructured":"Kawakami T, Yamazaki M, Mizoguchi M, Soma Y. Differences in anti-phosphatidylserine-prothrombin complex antibodies and cutaneous vasculitis between regular livedo reticularis and livedo racemosa. Rheumatology (Oxford). 2009;48:508\u201312.","journal-title":"Rheumatology (Oxford)"},{"key":"1202_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2133.1999.02622.x","volume":"140","author":"KM Acland","year":"1999","unstructured":"Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol. 1999;140:131\u20135.","journal-title":"Br J Dermatol"},{"key":"1202_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.5021\/ad.2015.27.5.614","volume":"27","author":"BJ So","year":"2015","unstructured":"So BJ, Park JB, Yoo MG, Kim IH, Son SW. Successful treatment of livedoid vasculitis with primary antiphospholipid syndrome by using aspirin and low dose warfarin combination therapy. Ann Dermatol. 2015;27:614\u20135.","journal-title":"Ann Dermatol"},{"issue":"1","key":"1202_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/acr.23584","volume":"71","author":"O Unlu","year":"2019","unstructured":"Unlu O, Erkan D, Barbhaiya M, et al. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the antiphospholipid syndrome alliance for clinical trials and international clinical database and repository. Arthritis Care Res Hoboken. 2019;71(1):134\u201341.","journal-title":"Arthritis Care Res Hoboken"},{"key":"1202_CR31","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.20433","volume":"50","author":"MG Tektonidou","year":"2004","unstructured":"Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004;50:2569\u201379.","journal-title":"Arthritis Rheum"},{"key":"1202_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","volume":"51","author":"M Barbhaiya","year":"2024","unstructured":"Barbhaiya M, Taghavi M, Zuily S, et al. Efforts to better characterize antiphospholipid antibody nephropathy for the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: renal pathology subcommittee report. J Rheumatol. 2024;51:150\u20139.","journal-title":"J Rheumatol"},{"key":"1202_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1006\/jaut.2000.0409","volume":"15","author":"M Petri","year":"2000","unstructured":"Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:145\u201351.","journal-title":"J Autoimmun"},{"key":"1202_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0852-7","volume":"21","author":"SA Stoots","year":"2019","unstructured":"Stoots SA, Lief L, Erkan D. Clinical insights into diffuse alveolar hemorrhage in antiphospholipid syndrome. Curr Rheumatol Rep. 2019;21: 56.","journal-title":"Curr Rheumatol Rep"},{"key":"1202_CR35","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.semarthrit.2014.10.013","volume":"44","author":"R Yachoui","year":"2015","unstructured":"Yachoui R, Sehgal R, Amlani B, Goldberg JW. Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. Semin Arthritis Rheum. 2015;44:652\u20137.","journal-title":"Semin Arthritis Rheum"},{"key":"1202_CR36","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","volume":"15","author":"I Rodr\u00edguez-Pint\u00f3","year":"2016","unstructured":"Rodr\u00edguez-Pint\u00f3 I, Moitinho M, Santacreu I, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the international CAPS registry. Autoimmun Rev. 2016;15:1120\u20134.","journal-title":"Autoimmun Rev"},{"key":"1202_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.autrev.2014.11.003","volume":"14","author":"G Denas","year":"2015","unstructured":"Denas G, Jose SP, Bracco A, Zoppellaro G, Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev. 2015;14:214\u201322.","journal-title":"Autoimmun Rev"},{"key":"1202_CR38","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1177\/0961203315572714","volume":"24","author":"CB Chighizola","year":"2015","unstructured":"Chighizola CB, Andreoli L, de Jesus GR, Banzato A, Pons-Estel GJ, Erkan D. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus. 2015;24:980\u20134.","journal-title":"Lupus"},{"key":"1202_CR39","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/art.10187","volume":"46","author":"R Cervera","year":"2002","unstructured":"Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019\u201327.","journal-title":"Arthritis Rheum"},{"key":"1202_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.semarthrit.2015.09.005","volume":"45","author":"SI Mavrogeni","year":"2016","unstructured":"Mavrogeni SI, Sfikakis PP, Kitas GD, Kolovou G, Tektonidou MG. Cardiac involvement in antiphospholipid syndrome: the diagnostic role of noninvasive cardiac imaging. Semin Arthritis Rheum. 2016;45:611\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"1202_CR41","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/art.27488","volume":"62","author":"K Sacr\u00e9","year":"2010","unstructured":"Sacr\u00e9 K, Brihaye B, Hyafil F, et al. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum. 2010;62:2093\u2013100.","journal-title":"Arthritis Rheum"},{"key":"1202_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-018-0484-5","volume":"20","author":"VO Puntmann","year":"2018","unstructured":"Puntmann VO, Valbuena S, Hinojar R, et al. Society for cardiovascular magnetic resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification. J Cardiovasc Magn Reson. 2018;20: 67.","journal-title":"J Cardiovasc Magn Reson"},{"key":"1202_CR43","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","volume":"32","author":"R Cervera","year":"2009","unstructured":"Cervera R, Bucciarelli S, Plas\u00edn MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the CAPS registry. J Autoimmun. 2009;32:240\u20135.","journal-title":"J Autoimmun"},{"key":"1202_CR44","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1210\/jc.2012-4300","volume":"98","author":"I Ramon","year":"2013","unstructured":"Ramon I, Mathian A, Bachelot A, et al. Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in the antiphospholipid syndrome: long-term outcome of 16 patients. J Clin Endocrinol Metab. 2013;98:3179\u201389.","journal-title":"J Clin Endocrinol Metab"},{"key":"1202_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520903659","volume":"48","author":"K Mleku\u0161 Kozamernik","year":"2020","unstructured":"Mleku\u0161 Kozamernik K, Jensterle M, Ambro\u017ei\u010d A, Pfeifer M. Adrenal failure and antiphospholipid syndrome. J Int Med Res. 2020;48: 300060520903659.","journal-title":"J Int Med Res"},{"key":"1202_CR46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/00005792-200303000-00005","volume":"82","author":"G Espinosa","year":"2003","unstructured":"Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine. 2003;82:106\u201318.","journal-title":"Medicine"},{"key":"1202_CR47","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1093\/humrep\/des251","volume":"27","author":"M Grande","year":"2012","unstructured":"Grande M, Borrell A, Garcia-Posada R, et al. The effect of maternal age on chromosomal anomaly rate and spectrum in recurrent miscarriage. Hum Reprod. 2012;27:3109\u201317.","journal-title":"Hum Reprod"},{"key":"1202_CR48","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/humrep\/des179","volume":"27","author":"M Sugiura-Ogasawara","year":"2012","unstructured":"Sugiura-Ogasawara M, Ozaki Y, Katano K, Suzumori N, Kitaori T, Mizutani E. Abnormal embryonic karyotype is the most frequent cause of recurrent miscarriage. Hum Reprod. 2012;27:2297\u2013303.","journal-title":"Hum Reprod"},{"key":"1202_CR49","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/acr.22066","volume":"65","author":"L Andreoli","year":"2013","unstructured":"Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken). 2013;65:1869\u201373.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1202_CR50","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.autrev.2014.02.003","volume":"13","author":"GR de Jesus","year":"2014","unstructured":"de Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13:795\u2013813.","journal-title":"Autoimmun Rev"},{"key":"1202_CR51","doi-asserted-by":"publisher","first-page":"hoy004","DOI":"10.1093\/hropen\/hoy004","volume":"2018","author":"R Bender Atik","year":"2018","unstructured":"Bender Atik R, Christiansen OB, Elson J, et al. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open. 2018;2018:hoy004.","journal-title":"Hum Reprod Open"},{"key":"1202_CR52","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.fertnstert.2019.11.025","volume":"113","author":"Definitions of infertility","year":"2020","unstructured":"Definitions of infertility. And recurrent pregnancy loss: a committee opinion. Fertil Steril. 2020;113:533\u20135.","journal-title":"Fertil Steril"},{"key":"1202_CR53","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1097\/01.AOG.0000465191.27155.25","volume":"125","author":"American College of Obstetricians and Gynecologists","year":"2015","unstructured":"American College of Obstetricians and Gynecologists. Early pregnancy loss. Obstet Gynecol. 2015;125:1258\u201367.","journal-title":"Obstet Gynecol"},{"key":"1202_CR54","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1097\/AOG.0b013e3181fe02ec","volume":"116","author":"AD do Prado","year":"2010","unstructured":"do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:1433\u201343.","journal-title":"Obstet Gynecol"},{"key":"1202_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.thromres.2011.02.006","volume":"128","author":"K Abou-Nassar","year":"2011","unstructured":"Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011;128:77\u201385.","journal-title":"Thromb Res"},{"key":"1202_CR56","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","volume":"135","author":"Gestational Hypertension and Preeclampsia","year":"2020","unstructured":"Gestational Hypertension and Preeclampsia. ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135:e237\u201360.","journal-title":"Obstet Gynecol"},{"key":"1202_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejogrb.2013.05.005","volume":"170","author":"E Abalos","year":"2013","unstructured":"Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170:1\u20137.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1202_CR58","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11926-007-0035-9","volume":"9","author":"EA Clark","year":"2007","unstructured":"Clark EA, Silver RM, Branch DW. Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep. 2007;9:219\u201325.","journal-title":"Curr Rheumatol Rep"},{"key":"1202_CR59","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.autrev.2015.01.008","volume":"14","author":"CA Viall","year":"2015","unstructured":"Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev. 2015;14:446\u201371.","journal-title":"Autoimmun Rev"},{"key":"1202_CR60","doi-asserted-by":"publisher","first-page":"B2","DOI":"10.1016\/j.ajog.2020.05.010","volume":"223","author":"JG Martins","year":"2020","unstructured":"Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal medicine consult series #52: diagnosis and management of fetal growth restriction: (Replaces clinical guideline number 3, April 2012). Am J Obstet Gynecol. 2020;223:B2\u201317.","journal-title":"Am J Obstet Gynecol"},{"key":"1202_CR61","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1097\/AOG.0000000000003070","volume":"133","author":"ACOG Practice Bulletin No","year":"2019","unstructured":"ACOG Practice Bulletin No. 204: fetal growth restriction. Obstet Gynecol. 2019;133:e97\u2013109.","journal-title":"Obstet Gynecol"},{"key":"1202_CR62","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1161\/CIRCULATIONAHA.111.028522","volume":"124","author":"S Zuily","year":"2011","unstructured":"Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies. Circulation. 2011;124:215\u201324.","journal-title":"Circulation"},{"key":"1202_CR63","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1161\/01.STR.0000170645.40562.09","volume":"36","author":"M Turiel","year":"2005","unstructured":"Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke. 2005;36:1490\u20134.","journal-title":"Stroke"},{"key":"1202_CR64","first-page":"2402","volume":"31","author":"NE Zavaleta","year":"2004","unstructured":"Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rhuematol. 2004;31:2402\u20137.","journal-title":"J Rhuematol"},{"key":"1202_CR65","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1161\/01.STR.0000154858.27353.df","volume":"36","author":"D Erdogan","year":"2005","unstructured":"Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke. 2005;36:592\u20136.","journal-title":"Stroke"},{"key":"1202_CR66","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/ard.2004.032813","volume":"64","author":"I Krause","year":"2005","unstructured":"Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1490\u20133.","journal-title":"Ann Rheum Dis"},{"key":"1202_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0002-9343(94)90108-2","volume":"96","author":"JL Vianna","year":"1994","unstructured":"Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med. 1994;96:3\u20139.","journal-title":"Am J Med"},{"key":"1202_CR68","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/0961203309353772","volume":"19","author":"J Pardos-Gea","year":"2010","unstructured":"Pardos-Gea J, Ordi-Ros J, Avegliano G, et al. Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus. 2010;19:575\u201382.","journal-title":"Lupus"},{"key":"1202_CR69","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0002-8703(99)70424-2","volume":"137","author":"N Esp\u00ednola-Zavaleta","year":"1999","unstructured":"Esp\u00ednola-Zavaleta N, Vargas-Barr\u00f3n J, Colmenares-Galvis T, et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J. 1999;137:973\u20138.","journal-title":"Am Heart J"},{"key":"1202_CR70","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1191\/0961203305lu2202oa","volume":"14","author":"F Tenedios","year":"2005","unstructured":"Tenedios F, Erkan D, Lockshin MD. Cardiac involvement in the antiphospholipid syndrome. Lupus. 2005;14:691\u20136.","journal-title":"Lupus"},{"key":"1202_CR71","first-page":"224","volume":"35","author":"CA Roldan","year":"2008","unstructured":"Roldan CA, Qualls CR, Sopko KS, Sibbitt WL. Jr. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. J Rhuematol. 2008;35:224\u20139.","journal-title":"J Rhuematol"},{"key":"1202_CR72","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.echo.2013.07.009","volume":"26","author":"RT Hahn","year":"2013","unstructured":"Hahn RT, Abraham T, Adams MS, et al. Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American society of echocardiography and the society of cardiovascular anesthesiologists. J Am Soc Echocardiogr. 2013;26:921\u201364.","journal-title":"J Am Soc Echocardiogr"},{"key":"1202_CR73","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/0961203310395052","volume":"20","author":"R Cervera","year":"2011","unstructured":"Cervera R, Tektonidou MG, Espinosa G, et al. Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (II): thrombocytopenia and skin manifestations. Lupus. 2011;20:174\u201381.","journal-title":"Lupus"},{"key":"1202_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrcardio.2012.7","volume":"9","author":"B Rem\u00e9nyi","year":"2012","unstructured":"Rem\u00e9nyi B, Wilson N, Steer A, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease\u2013an evidence-based guideline. Nat Rev Cardiol. 2012;9:297\u2013309.","journal-title":"Nat Rev Cardiol"},{"key":"1202_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","volume":"32","author":"C Mitchell","year":"2019","unstructured":"Mitchell C, Rahko PS, Blauwet LA, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American society of echocardiography. J Am Soc Echocardiogr. 2019;32:1\u201364.","journal-title":"J Am Soc Echocardiogr"},{"key":"1202_CR76","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","volume":"74","author":"R Cervera","year":"2015","unstructured":"Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74:1011\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1202_CR77","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.autrev.2019.102395","volume":"18","author":"YP Chock","year":"2019","unstructured":"Chock YP, Moulinet T, Dufrost V, Erkan D, Wahl D, Zuily S. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev. 2019;18:102395.","journal-title":"Autoimmun Rev"},{"key":"1202_CR78","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/jth.13763","volume":"15","author":"R Hisada","year":"2017","unstructured":"Hisada R, Kato M, Sugawara E, et al. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study. J Thromb Haemost. 2017;15:1782\u20137.","journal-title":"J Thromb Haemost"},{"key":"1202_CR79","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3899\/jrheum.130984","volume":"41","author":"B Artim-Esen","year":"2014","unstructured":"Artim-Esen B, \u00c7ene E, \u015eahinkaya Y, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol. 2014;41:1304\u201310.","journal-title":"J Rheumatol"},{"key":"1202_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejim.2020.10.011","volume":"84","author":"T Moulinet","year":"2021","unstructured":"Moulinet T, Dufrost V, Clerc-Urm\u00e8s I, Wahl D, Zuily S. Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia. Eur J Intern Med. 2021;84:101\u20133.","journal-title":"Eur J Intern Med"},{"key":"1202_CR81","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","volume":"13","author":"Q Reynaud","year":"2014","unstructured":"Reynaud Q, Lega JC, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13:595\u2013608.","journal-title":"Autoimmun Rev"},{"key":"1202_CR82","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829\u201366.","journal-title":"Blood Adv"},{"key":"1202_CR83","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/00003246-200006000-00031","volume":"28","author":"S Vanderschueren","year":"2000","unstructured":"Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28:1871\u20136.","journal-title":"Crit Care Med"},{"key":"1202_CR84","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1378\/chest.10-2243","volume":"139","author":"P Hui","year":"2011","unstructured":"Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011;139:271\u20138.","journal-title":"Chest"},{"key":"1202_CR85","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1365-2141.2009.07842.x","volume":"147","author":"JC Marsh","year":"2009","unstructured":"Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43\u201370.","journal-title":"Br J Haematol"},{"key":"1202_CR86","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/ijlh.12221","volume":"36","author":"M Levi","year":"2014","unstructured":"Levi M. Diagnosis and treatment of disseminated intravascular coagulation. Int J Lab Hematol. 2014;36:228\u201336.","journal-title":"Int J Lab Hematol"},{"key":"1202_CR87","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s002280050272","volume":"52","author":"U Pedersen-Bjergaard","year":"1997","unstructured":"Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol. 1997;52:183\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1202_CR88","doi-asserted-by":"publisher","unstructured":"George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematol Am Soc Hematol Educ Program. 2009;153\u20138. https:\/\/doi.org\/10.1182\/asheducation-2009.1.153.","DOI":"10.1182\/asheducation-2009.1.153"},{"key":"1202_CR89","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","volume":"101","author":"M Galli","year":"2003","unstructured":"Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827\u201332.","journal-title":"Blood"},{"key":"1202_CR90","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","volume":"8","author":"RT Urbanus","year":"2009","unstructured":"Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8:998\u20131005.","journal-title":"Lancet Neurol"},{"key":"1202_CR91","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/0961203310395803","volume":"20","author":"G Ruiz-Irastorza","year":"2011","unstructured":"Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus. 2011;20:206\u201318.","journal-title":"Lupus"},{"key":"1202_CR92","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.thromres.2014.10.013","volume":"135","author":"V Pengo","year":"2015","unstructured":"Pengo V, Testa S, Martinelli I, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res. 2015;135:46\u20139.","journal-title":"Thromb Res"},{"key":"1202_CR93","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jth.14261","volume":"16","author":"W Chayoua","year":"2018","unstructured":"Chayoua W, Kelchtermans H, Moore GW, et al. Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-\u03b22glycoprotein I antibody detection assays. J Thromb Haemost. 2018;16:2016\u201323.","journal-title":"J Thromb Haemost"},{"key":"1202_CR94","doi-asserted-by":"publisher","DOI":"10.1055\/a-1344-4271","author":"D Yin","year":"2020","unstructured":"Yin D, de Groot PG, Ninivaggi M, Devreese KMJ, de Laat B. Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome. Thromb Haemost. 2020. https:\/\/doi.org\/10.1055\/a-1344-4271.","journal-title":"Thromb Haemost"},{"key":"1202_CR95","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00916-5","volume":"22","author":"KMJ Devreese","year":"2020","unstructured":"Devreese KMJ. How to interpret antiphospholipid laboratory tests. Curr Rheumatol Rep. 2020;22: 38.","journal-title":"Curr Rheumatol Rep"},{"key":"1202_CR96","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1309\/AJCP4SPPLG5XVIXF","volume":"134","author":"FR Dembitzer","year":"2010","unstructured":"Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by North American clinical laboratories. Am J Clin Pathol. 2010;134:764\u201373.","journal-title":"Am J Clin Pathol"},{"key":"1202_CR97","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/jth.12537","volume":"12","author":"KM Devreese","year":"2014","unstructured":"Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12:792\u20135.","journal-title":"J Thromb Haemost"},{"key":"1202_CR98","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/ijlh.13094","volume":"41","author":"J Devignes","year":"2019","unstructured":"Devignes J, Sma\u00efl-Tabbone M, Herv\u00e9 A, et al. Extended persistence of antiphospholipid antibodies beyond the 12-week time interval: association with baseline antiphospholipid antibodies titres. Int J Lab Hematol. 2019;41:726\u201330.","journal-title":"Int J Lab Hematol"},{"key":"1202_CR99","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/jth.13379","volume":"14","author":"H Kelchtermans","year":"2016","unstructured":"Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. IgG\/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. J Thromb Haemost. 2016;14:1530\u201348.","journal-title":"J Thromb Haemost"},{"key":"1202_CR100","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/ijlh.12466","volume":"38","author":"B Montaruli","year":"2016","unstructured":"Montaruli B, De Luna E, Erroi L, et al. Analytical and clinical comparison of different immunoassay systems for the detection of antiphospholipid antibodies. Int J Lab Hematol. 2016;38:172\u201382.","journal-title":"Int J Lab Hematol"},{"key":"1202_CR101","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/jth.14633","volume":"18","author":"W Chayoua","year":"2020","unstructured":"Chayoua W, Kelchtermans H, Gris JC, et al. The (non-)sense of detecting anti-cardiolipin and anti-\u03b22glycoprotein I IgM antibodies in the antiphospholipid syndrome. J Thromb Haemost. 2020;18:169\u201379.","journal-title":"J Thromb Haemost"},{"key":"1202_CR102","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1161\/01.STR.28.9.1660","volume":"28","author":"SR Levine","year":"1997","unstructured":"Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke. 1997;28:1660\u20135.","journal-title":"Stroke"},{"key":"1202_CR103","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.thromres.2004.08.009","volume":"114","author":"M Galli","year":"2004","unstructured":"Galli M. Antiphospholipid antibodies and thrombosis: do test patterns identify the patients\u2019 risk? Thromb Res. 2004;114:597\u2013601.","journal-title":"Thromb Res"},{"key":"1202_CR104","first-page":"101","volume":"82","author":"G Finazzi","year":"1997","unstructured":"Finazzi G. The Italian registry of antiphospholipid antibodies. Haematologica. 1997;82:101\u20135.","journal-title":"Haematologica"},{"key":"1202_CR105","first-page":"1775","volume":"33","author":"A Danowski","year":"2006","unstructured":"Danowski A, Kickler TS, Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rhuematol. 2006;33:1775\u20139.","journal-title":"J Rhuematol"},{"key":"1202_CR106","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1751-553X.2012.01448.x","volume":"34","author":"F Van Hoecke","year":"2012","unstructured":"Van Hoecke F, Persijn L, Decavele AS, Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2012;34:630\u201340.","journal-title":"Int J Lab Hematol"},{"key":"1202_CR107","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/jalm\/jfaa072","volume":"5","author":"S Zuily","year":"2020","unstructured":"Zuily S, de Laat B, Guillemin F, et al. Anti-domain I \u03b22-glycoprotein I antibodies and activated protein C resistance predict thrombosis in antiphospholipid syndrome: TAC(I)T study. J Appl Lab Med. 2020;5:1242\u201352.","journal-title":"J Appl Lab Med"},{"key":"1202_CR108","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/PAT.0000000000000070","volume":"46","author":"A Brusch","year":"2014","unstructured":"Brusch A, Bundell C, Hollingsworth P. Immunoglobulin G is the only anti-beta-2-glycoprotein I isotype that associates with unprovoked thrombotic events among hospital patients. Pathology. 2014;46:234\u20139.","journal-title":"Pathology"},{"key":"1202_CR109","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1111\/jth.12264","volume":"11","author":"V Pengo","year":"2013","unstructured":"Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost. 2013;11:1527\u201331.","journal-title":"J Thromb Haemost"},{"key":"1202_CR110","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/0961203316657433","volume":"26","author":"CM Yelnik","year":"2017","unstructured":"Yelnik CM, Urbanski G, Drumez E, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26:163\u20139.","journal-title":"Lupus"},{"key":"1202_CR111","doi-asserted-by":"crossref","unstructured":"Gkrouzman E, Sevim E, Finik J et al. Antiphospholipid antibody profile stability over time: prospective results from the APS ACTION clinical database and repository. The Journal of rheumatology 2020.","DOI":"10.3899\/jrheum.200513"},{"key":"1202_CR112","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1177\/0961203320954520","volume":"29","author":"GR de Jes\u00fas","year":"2020","unstructured":"de Jes\u00fas GR, Benson AE, Chighizola CB, Sciascia S, Branch DW. 16th international congress on antiphospholipid antibodies task force report on obstetric antiphospholipid syndrome. Lupus. 2020;29:1601\u201315.","journal-title":"Lupus"},{"key":"1202_CR113","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1111\/jth.15047","volume":"18","author":"KMJ Devreese","year":"2020","unstructured":"Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18:2828\u201339.","journal-title":"J Thromb Haemost"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01202-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-025-01202-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-025-01202-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:03:49Z","timestamp":1770750229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-025-01202-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1202"],"URL":"https:\/\/doi.org\/10.1007\/s11926-025-01202-y","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"41"}}